#Pharmaceuticals4

2 Oct 2025

Affordable twice-yearly HIV injection lenacapavir to reach 120 countries

Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.

A1 A2 B1 B2 Read

Photo by Spencer Davis, Unsplash

27 Aug 2025

Coartem Baby: first malaria medicine for newborns

Swissmedic approved Coartem Baby in July 2025, the first antimalarial made for newborns under five kilograms. The tablet aims to close a long treatment gap in malaria-endemic parts of Sub-Saharan Africa.

Level

A1 A2 B1 B2 Read

21 Oct 2024

Lenacapavir: six-month injection to prevent HIV

Lenacapavir is a long-acting injectable for HIV prevention that is given every six months. Experts say its effect will depend on price, supply and how quickly approvals and generic production reach countries in Africa and beyond.

Level

A1 A2 B1 B2 Read

12 Jul 2024

Olfat Berro: improving health access in the Middle East

Olfat Berro grew up in Lebanon and chose a career to improve health services and medicine access in the region. She rose at Roche, launched training programmes and led large public health collaborations in Egypt and elsewhere.

Level

A1 A2 B1 B2 Read

No more articles